<DOC>
	<DOCNO>NCT02727647</DOCNO>
	<brief_summary>Title : Comparison different prophylaxis regimens hemophilia A pediatric patient Principal Investigator : Assistant Professor Darintr Sosothikul , MD Research Question : Does different factor VIII dosage effect outcome hemophilia treatment term breakthrough bleeding , number hospital stay day-off school ? Type Research : Clinical research Study design : Single center clinical trial Concise methodology : 1 . Study Population : Children hemophilia A received treatment KCMH May 2015 March 2016 enrol study . The consent obtain study . 2 . Observation measurement : 1 . History , interest clinical data laboratory data record Clinical record Form ( CRF ) 2 . Measurement : . Complete blood count ( CBC ) , Factor VIII level , Factor VIII inhibitor level ii . Number breakthrough bleeding , number hospital stay day-off school iii . Joint score Hemophilia Joint Health Score 2.1 iv . EQ-5D-5L quality life assessment score 3 . Data analysis : The p-value le 0.05 consider statistically significant . Mann-Whitney test use test correlation variable ( CBC , Factor VIII level , Factor VIII inhibitor level , Number breakthrough bleeding , number hospital stay , day-off school , Hemophilia Joint Health Score 2.1 , EQ-5D-5L quality life assessment score ) Sample size : 16 patient Potential impact : The outcome different factor VIII concentrate dose 15-20 U/kg/dose 2 times/week 35-40 U/kg/dose 1 time/week reveal . These outcome include number breakthrough bleeding , number hospital stay , day-off school , joint health quality life . The result study guide study optimal dose duration factor VIII treatment hemophilia A patient future .</brief_summary>
	<brief_title>Comparison Different Prophylaxis Regimens Moderate Severe Hemophilia A Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Hemophilia patient moderate ( factor level 13 % ) severe ( factor level &lt; 1 % ) severity Platelet count le 100,000 /mm3 bleeding tendency Hemophilia patient FVIII inhibitor &gt; 0.6 BU ( modify Nijmogen method ) Hemophilia patient bleed symptom</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Moderate hemophilia A</keyword>
	<keyword>Severe hemophilia A</keyword>
	<keyword>Intermediate dose prophylaxis</keyword>
	<keyword>Low dose prophylaxis</keyword>
</DOC>